Search clinical trials for: SHR4640 dose1

Total 5532 results

Innovent Biologics (Suzhou) Co. Ltd.

Completed

Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects

Healthy Subjects

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia

Hyperuricemia
Jiangsu HengRui Medicine Co., Ltd.

Unknown

The Drug-Drug Interaction of SHR4640 and Febuxostat in Patients With Hyperuricemia

Hyperuricemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout

Gout

China
Atridia Pty Ltd.

Completed

A Single Dose Study of SHR4640 in Healthy Male Volunteers

Gout

Australia
Jiangsu HengRui Medicine Co., Ltd.

Completed

Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects

Hyperuricemia

China
Taiho Pharmaceutical Co., Ltd.

Recruiting

A Study of TAS3731 in Healthy Adults

Healthy Adult Males

Japan
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects

Hyperuricemia

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study on the Food Effects of Oral SHR4640 Tablets in Healthy Volunteers

Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers

Hyperuricemia | Primary Gout
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR4640 in Chinese Healthy Adult Male Volunteers.

Healthy Adult Male Volunteers

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Multiple Dose Study of SHR4640 in Healthy Subjects

Gout; Hyperuricemia

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment

Hepatic Impairment

China
Atridia Pty Ltd.

Completed

Multiple Doses Study of SHR4640 in Male Subjects With High Serum Uric Acid Level

Hyperuricemia | Gout

Australia
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia

Primary Gout and Hyperuricemia
Jiangsu HengRui Medicine Co., Ltd.

Completed

Single Dose Study of SHR4640 in Healthy Subjects

Gout; Hyperuricemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval

Gout and Hyperuricemia

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Relative Bioavailability Study of SHR3680 (SHR-3680)

Healthy Male Subjects

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients

Hormone Refractory Prostate Cancer | Metastatic Prostate Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects

Castration-Resistant Prostate Cancer

China
Institute of Medical Biology, Chinese Academy of...
Guangxi Center for Disease Control and Prevention

Completed

Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV

Poliomyelitis

China
Reata, a wholly owned subsidiary of Biogen

Withdrawn

Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma

Malignant Melanoma
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC

Prostate Cancer | Castration-resistant Prostate Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC

Prostate Cancer | Castration-resistant Prostate Cancer

China
Atridia Pty Ltd.

Completed

A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer

Prostate Cancer | Neoplasm

Australia
Jiangsu HengRui Medicine Co., Ltd.

Completed

Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia

Hyperuricemia

China
Galapagos NV

Completed

First-in-Human Single and Multiple Dose of GLPG2222

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42721458 in Healthy Male Participants

Healthy

Belgium
Chiesi Farmaceutici S.p.A.
SGS S.A.

Completed

Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD

COPD

United Kingdom
Guangzhou Henovcom Bioscience Co. Ltd.

Completed

A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.

Healthy

United States
Guangzhou JOYO Pharma Co., Ltd
Chengdu JOYO pharma Co., Ltd.

Not yet recruiting

A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy Participants

Hepatic Impairment | Healthy Participants

China
Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

Safety, Tolerability and Pharmacokinetics of FTP-198 in Healthy Australian Volunteers

Healthy

Australia
GEN İlaç ve Sağlık Ürünleri A.Ş.
Sulfateq B.V.

Recruiting

A First-In-Human Study of Single and Multiple Ascending Doses of Oral SUL-238 in Healthy Subjects

Healthy Subjects

Turkey
Hospital de Mataró

Completed

Effect Of Piperine In Patients With Oropharyngeal Dysphagia (FIS 2009_2)

Deglutition Disorders

Spain
Enterprise Therapeutics Ltd

Completed

A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects

Cystic Fibrosis

United Kingdom
Sinew Pharma Inc.

Terminated

An Open-Label Study to Assess the Hepatic Protection Effect of SNP-612, in Patients With NAFLD

NASH - Nonalcoholic Steatohepatitis

Taiwan
Galapagos NV

Completed

First-in-Human Single and Multiple Dose of GLPG1837

Healthy

Belgium
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer

Prostate Cancer | Hormone-Dependent Prostate Cancer

China, Czechia, Poland, Bulgaria
Apnimed

Completed

AD109 Dose Finding in Mild to Moderate OSA

Obstructive Sleep Apnea

United States
Duke University
Centers for Disease Control and Prevention

Completed

Alternate Dosing Schedules Study for HPV Vaccine (ADS) (ADS)

Cervical Cancer | Genital Warts

United States
Chinook Therapeutics, Inc.

Active, not recruiting

Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)

IgA Nephropathy

Korea, Republic of, United States, United Kingdom
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC

Prostate Cancer Metastatic

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy

Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

China
Pfizer

Completed

Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally

Fungal Infection

Netherlands
Rutgers, The State University of New Jersey
Centers for Disease Control and Prevention

Completed

Experimentally Testing the Effectiveness of a Campus-based Bystander Intervention

Violence | Helping Behavior | Sexual Assault and Rape | Assaultive Behavior

United States
Chiesi Farmaceutici S.p.A.

Completed

Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD (CARSAF)

Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Bulgaria, Germany, Hungary, Poland, Russian Federation, United Kingdom
Suzhou Alphamab Co., Ltd.

Recruiting

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia

Hemophilia

China
Pluristem Ltd.

Completed

Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)

Intermittent Claudication | Peripheral Artery Disease

United States, Germany, Korea, Republic of, Israel
Frequency Therapeutics

Completed

FX-322 in Adults With Stable Sensorineural Hearing Loss

Sensorineural Hearing Loss | Noise Induced Hearing Loss | Sudden Sensorineural Hearing Loss

United States

Search clinical trials for: SHR4640 dose1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations